Time on boards
- Boards served
- 3
- Current seats
- 3
- Board service
- 6 years
- Director since
- 2023
6 years of board service in total across 3 boards, counting each seat separately. Longest: Edgewise Therapeutics Inc., 3 years.
Shareholder support
Support is votes for as a share of votes for and against (or withheld). Below 80% is a clear protest.
-
Edgewise Therapeutics Inc. June 4, 202665.0%
-
Edgewise Therapeutics Inc. June 9, 202377.4%
Insider trades
All notable trades →From SEC Forms 4 and 5. Open-market purchases and sales are highlighted; grants, option exercises and shares withheld for tax are routine.
| Date | Company | Transaction | Shares | Price | Value |
|---|---|---|---|---|---|
| Oct 5, 2026 | Omada Health Inc. | Grant or award | +694 | — | — |
| Jul 5, 2026 | Omada Health Inc. | Grant or award | +820 | — | — |
| Jun 16, 2026 | Omada Health Inc. | Grant or award | +10,882 | — | — |
| Jun 3, 2026 | Carlsmed Inc. | Grant or award | +13,698 | — | — |
| Apr 5, 2026 | Omada Health Inc. | Grant or award | +882 | — | — |
| Jan 5, 2026 | Omada Health Inc. | Grant or award | +915 | — | — |
| Dec 2, 2025 | Omada Health Inc. | Other | +167,748 | — | — |
| Dec 2, 2025 | Omada Health Inc. | Other | −4,571,769 | — | — |
| Dec 2, 2025 | Omada Health Inc. | Other | −146,257 | — | — |
| Oct 5, 2025 | Omada Health Inc. | Grant or award | +657 | — | — |
| Jul 24, 2025 | Carlsmed Inc. | Derivative conversion | +2,948,794 | — | — |
| Jul 24, 2025 | Carlsmed Inc. | Derivative conversion | +825,135 | — | — |
| Jul 24, 2025 | Carlsmed Inc. | Derivative conversion | +531,877 | — | — |
| Jul 24, 2025 | Carlsmed Inc. | Derivative conversion | +149,655 | — | — |
| Jul 24, 2025 | Carlsmed Inc. | Derivative conversion | +41,876 | — | — |
Questions about Jonathan D. Root
What boards is Jonathan D. Root on?
Jonathan D. Root sits on the boards of Carlsmed Inc., Edgewise Therapeutics Inc. and Omada Health Inc.
How long has Jonathan D. Root served on boards?
Our records show at least 6 years of board service across 3 boards, the earliest from 2023.
Reviews (0)
Sign in to write a review.
No reviews yet. Be the first to write one.